Expression of Concern: Adult Bone Marrow Neural Crest Stem Cells and Mesenchymal Stem Cells Are Not Able to Replace Lost Neurons in Acute MPTP-Lesioned Mice

The authors explained that this study follows up from the results previously described in their Cellular and Molecular Life Sciences and PLOS ONE articles [2, 3 retracted in 6, 4], and preludes their PLOS ONE article [5], and clarify that the SOX10 panel in Fig 1D and the Nestin panel in Fig 1E represent the same experimental conditions as those panels presented in their other publications. As the original Figures presented in Fig 1D and 1E are not licensed for reproduction and distribution under the terms of the Creative Commons Attribution License (or Public Domain License for US gov), this article was republished on October 28, 2021 to remove this content and replace it with alternative relevant immunological characterization images. Please download this article again to view the correct version. Furthermore, the authors explain that the wrong images were used to prepare the Fig 5A MPTP effect SNpc and MTPT + NCSC Stratum 70 days panels, the Fig 5C SNpc panel and the S1B Fig 70 days panel. The authors clarify that the wrong images were used inadvertently during figure preparation and explain that this error was introduced during the preparation of the figure; the correct samples were used for the quantification and the preparation of the associated graphs. The updated figures below were provided to relay the correct panels for Fig 5, but the authors explained that they were unable to provide a replacement panel for the S1B Fig 70 days result and S1 Fig has been updated to remove the incorrect panel. The originally published, uncorrected version of S1 Fig is provided in the S6 File below. PLOS ONE


Introduction
The treatment of neurological disorders represents a critical issue in clinical research, since no complete functional recovery can be achieved with current therapeutic means, despite symptomatic improvements. Indeed, whereas restricted brain areas still house cells competent to generate newborn neurons in adulthood [1,2], this limited neurogenesis does not seem to be sufficient to enable neuronal regeneration in cases of lesions of the central nervous system. Therefore, other sources of neural cells have to be considered in a cell therapy objective. Stem cells are characterized as cells endowed with continuous self-renewal ability and pluri-or multipotentiality [3], and could consequently give rise to a wide panel of cell types, including neural cells. Indeed, while neurons have already been successfully generated from embryonic stem cells (ES) [4,5] or induced pluripotent stem cells (iPS) [6,7], the use of adult somatic stem cells definitely remains of significant interest regarding technical, ethical and immunological issues concerning cell transplantation for brain-related diseases. In this regard, bone marrow stromal cells (BMSC) represent an important source of easily-accessible multipotent cells to use in a cell therapy purpose [8].
Numerous studies already described cell therapy experiments using BMSC and explored their neuronal plasticity in vivo [9][10][11]. However, result discrepancies appeared in those studies, which could mainly reside in the lack of exact phenotypic characterization of BMSC, due to the absence of specific membrane markers and non-standardized culture methods. Consequently, several groups described BMSC with major different phenotypes: Verfaillie's group described a rare population of cells in human BM stroma as mesodermal adult progenitor cells [12,13]; D'Ippolito and collaborators cultured cells in low oxygen tension and characterized marrow isolated adult multilineage inducible cells [14,15]; whereas a lot of other groups kept the mesenchymal stem cell (MSC) concept as defined by Pittenger et al. [16]. In addition to the phenotypic differences of BMSC which are inherent to culture settings, it has been demonstrated that BMSC are constituted by a mixed population of cells arising from different embryonic lineages. Indeed, although adult BMSC were commonly considered to be of mesodermal origin [17], several studies have conclusively shown that some adult BMSC derive from the neural crest [8,[18][19][20][21].
The main objective of this study was consequently to specifically analyze the capacity of in vivo differentiation of the two distinct populations of BMSC: mesenchymal stem cells (MSC) and neural crest stem cells (NCSC), both isolated from adult bone marrow and recently characterized by Wislet-Gendebien et al. [21,22], when injected into lesioned brain. Indeed, we know that bone marrow NCSC are present in low proportion inside primary BMSC cultures compared to the MSC [22]. Consequently, a graft of pure bone marrow NCSC could lead to different results than observed with BMSC and could be able to restore brain lesions through a neural differentiation process in a larger extent, due to their neural crest developmental origin. We therefore grafted NCSC and MSC pure populations into the brain of mice characterized by dopaminergic nigrostriatal pathway lesions (mimicking the dopaminergic cell loss in advanced stages of Parkinson's disease) induced by previous 1-methyl-4-phenyl-2,3,5tetrahydropyridine hydrochloride (MPTP-HCl) injections. We then investigated neural differentiation events and downstream effects on the nigrostriatal pathway integrity, in order to evaluate potential of NCSC and MSC therapeutic abilities once inside the lesioned brain.

Animal Care
Wnt1-Cre/R26R-LacZ double transgenic mice were used to isolate NCSC and MSC clones from adult bone marrow stromal cells cultures [22]. 12 to 16-week-old wild type C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME, USA) were used as recipient mice for graft experiments. Animals were bred at the University of Liège Central Animal facility and experiments were performed in accordance with the rules set by the local animal ethics committee (ethical permit 1038) as well as the Swiss Academy of Medical Sciences.

Genomic Validation of Wnt1-CRE/R26R-LacZ Recombination
DNA was isolated from NCSC mix and MSC mix using the QIAamp DNA Mini Kit extraction protocol (Qiagen, Germantown, MD, USA). Briefly, cells were incubated at 56uC with proteinase K in a lysis buffer for 10 min, then genomic DNA was purified through several silica-membrane-based steps (see manufacturer's instructions). DNA amount was then calculated via a NanoDrop spectrophotometer (Thermo Scientific). Afterwards, DNA sequences of interest were amplified by polymerase chain reaction by mixing 500 ng of genomic DNA with Taq Polymerase (Promega) and specific primers (PGK-Neo: For-ATGGATTG-CACGCAGGTTCTCC; Rev-CAGAAGAACTCGTCAA-GAAGGC and actin: For-ATCTTGATCTTCATGGTGC-TAGG; Rev-TGTTACCAACTGGGACGACATGG) in a T3000 thermocycler (Biometra, Göttingen, Germany).

Cell Preparation and Transplantation
Just before the transplantation, two cell solutions containing respectively 5 NCSC clones and 5 MSC clones in equal numbers were prepared. Whereas NCSC mix were already traceable thanks to their b-galactosidase activity, we needed to label MSC mix with Cell Tracker Green (CTG) (Life Technologies) to allow their traceability in vivo. Mice were anesthetized with 100 mg/kg of a solution containing equivalent volumes of xylazine (Rompun, Bayer, Belgium) and ketamine (Ketalar, Pfijzer, Belgium). They were then placed into a stereotaxic frame (Benchmark, MyNeur-oLab.com) and received one injection of 5610 4 cells suspended in 2 mL PBS (Life Technologies) in the right striatum (0,5 mm anterior, 2 mm lateral and 3 mm ventral, with respect to bregma). The intracerebral injection was performed using a Hamilton's 5 ml syringe, coupled with a 26-gauge needle. The needle was left in place for few minutes before being retracted, to avoid reflux along the injection track. After the surgery, mice were placed under a warm lamp until their complete awakening.

Brain Processing
At different delays following cell transplantation, animals were anesthetized with pentobarbital and sacrificed by intracardiac perfusion of ice-cold PBS, followed by paraformaldehyde (PFA) 4% (in PBS 0,1 M), at. Skulls were dissected and brains were immediately removed, post-fixed for 2 hours at 4uC in the same fixative then immersed overnight in a solution of sucrose 20% (in PBS 0,1 M). They were frozen by slow immersion in isopentane cooled on dry-ice. Coronal 14 mm-sections were cut using a cryostat, mounted on positively charged slides, and stored in 220uC for further experiments (30 slides covering the entirety of the striatum and 10 slides covering the entirety of the midbrain).

DNA Extraction from Striatal Slices and PCR Validation of Survival Rate Evaluation
DNA was extracted from 14 mm-striatal slices (after 220uC storage) using the PrepFiler Forensic DNA Extraction Kit (Life Technologies). Right striatum was microdissected on about 10 slices and then scraped into a 1,5 mL microcentrifuge tube. After lysis with proteinase K and heat/shake treatment, genomic DNA was bound to PrepFiler Magnetic Particles and then eluted in order to amplify sequences of interest by PCR (See Genomic validation of Wnt1-CRE/R26R-LacZ recombination section).
The same steps and panel of primary antibodies were used for immunochemistry, but stainings were acquired using peroxydasecoupled secondary antibodies (1:500, Dako) and diaminobenzidine revelation.
Image acquisition and analysis were performed using a Zeiss AxioImager Z1 epifluorescent microscope (Zeiss, Zaventem, Belgique) coupled with FluoView software (Olympus, Artselaar, Belgique), and Olympus AX-70 microscope (Olympus) coupled with AnalySIS software (Olympus). The digitized images were adjusted for brightness and contrast, color-coded, and merged, when appropriate, using the NIH program ImageJ (Wayne Rasband, National Institute of Mental Health, Bethesda, MD, USA).
Carazzi hematoxylin coloration. Dry brain sections were placed in denatured ethanol and slightly heated for approximately 4 minutes, then were washed three times in milliQ water, before an incubation of 10 minutes in Carazzi hematoxylin. After three washes in water, sections were finally mounted with Q Path Safemount (Labonord).

Quantification of Cell Survival and Number of Neurons in the SN and VTA
Cell survival was quantified as followed: To evaluate the number of NCSC mix in the brains at each time point posttransplantation, X-gal staining was performed on 4 slides containing striatal slices (4 slides covering the 30 slides : e.g. slide 1-10-20 -25). Nuclei were counterstained with Hoescht, and after superposition of X-gal/Hoescht staining, X-gal positive nuclei were counted in each striatal sections on the slides. We then normalized the number of X-gal positive nuclei for all the 30 sections covering the entirety of striatum, and expressed this number in % regarding the 5610 4 cells that were initially injected. To evaluate the number of MSC mix in the brains at each time point post-transplantation, co-localization of Cell Tracker Green and Hoescht was used and the same countings and normalizations were performed.
To evaluate the nigrostriatal pathway integrity, SNpc and VTA neurons were counted as previously described in the followed MPTP-administration protocol [23]. Our neuronal counts were expressed as mean number of neurons per representative mesencephalic plane. For each mouse, sections covering the entire rostrocaudal axis of the mesencephalon were analyzed. The mean number of neurons for each representative mesencephalic plane was obtained by averaging the number of neurons counted from both right and left SNpc or VTA areas, respectively.

Statistical Analysis
Data were analyzed statistically using Statistica 10 program (StatSoft, Tulsa, OK, USA). Results are reported as mean 6 standard error of mean, with the n described as the number of mice in each group. Level of statistical significance was set at p,0.05.

Clonal Selection of NCSC and MSC from Adult Bone Marrow
Since we previously demonstrated that neural crest stem cells were mainly composed of nestin-positive cells [22] and that the number of nestin-positive cells increased with the number of passages [25], we decided to perform clonal selection of NCSC and MSC starting from passage 5, which should theoretically give us equal chances to isolate NCSC or MSC. Single cell BMSC were placed in a 96-wells plate in MesenCult medium allowing 1.2% of cells to proliferate. NCSC clones or MSC clones were then pooled together creating two distinct and pure population: NCSC mix and MSC mix. We first verified that cells in NCSC mix were effectively derived from initial embryonic neural crest cells that underwent Cre-Lox recombination, conversely to MSC clones that were not neural crest-derived ( Fig. 1 A-B). NCSC mix (b-galactosidasepositive cells ; Fig 1.C) and MSC mix (b-galactosidase-negative cells; Fig 1.D) were then characterized in vitro. As previously described [22], NCSC mix were Sox10-positive (Fig 1.D), nestin-positive ( Fig. 1.E) and p75 NTR -positive ( Fig. 1.F) while MSC mix were Sox10-negative ( Fig. 1.L), less than 15% were nestin-positive (Fig 1.M) and weakly p75 NTR -positive ( Fig. 1.N). MSC mix also expressed Fzd-4 ( Fig. 1.Q), Sca-1 ( Fig. 1.O) and CD24 ( Fig. 1.P) while NCSC mix were only positives for Fzd-4 ( Fig. 1.I). Additionally, bIII-tubulin positive cells were observed in NCSC mix when cultivated in Mesencult medium (without any differentiation protocol, Fig. 1.J). At the opposite, no bIII-tubulin positive cells were observed among MSC mix (Fig. 1.R). However, NCSC mix and MSC mix were both negative for more mature or specific neuronal markers like MAP2ab or TH and for GFAP (data not shown). We then decided to characterize NCSC mix and MSC mix differentiation and therapeutic abilities in vivo using the MPTP mouse model.

MPTP Mouse Model Validation
In order to verify MPTP-injection impact on nigrostriatal system (classically affected in Parkinson's disease) and validate our experimental model, we quantified the number of dopaminergic neurons by immunostaining of tyrosine hydroxylase (TH) (limiting enzyme in dopamine synthesis). As observed on Fig. 2.A, a drastic decrease in TH-positive fibers in the entire striatum was observed in MPTP-treated animals compared to control (.95%). At the midbrain level, TH-positive cell bodies in the Substantia Nigra pars compacta (SNpc) of MPTP-treated mice were quantified (45,9365,86 cells per representative mesencephalic plane, n = 5) and revealed a significant decrease (60%) of the number of cells compared to the control condition (129,40610,50 TH-positive neurons per representative mesencephalic plane; n = 5; One-way ANOVA, p,0,001; Fig. 2.A-B). Ventral tegmental area (VTA) provides an internal control zone: VTA dopaminergic neurons were affected by MPTP in a lesser extent than SNpc neurons [26], and the difference between controls and MPTP-treated animals was not significant, attesting of MPTP specificity for SNpc neurons (One-way ANOVA, p.0,05). Those results were consistent with already published studies [23] (Fig. 2.A-B).

NCSC mix and MSC mix Survival Rate
NCSC mix and MSC mix were injected in mice striatum 5 days post-MPTP injection. Surviving cells were quantified after 3, 7, 14, 28 and 70 days following cell graft, on all brain sections by counting nuclei co-localizing with X-gal staining or Cell Tracker Green (CTG) (for respectively grafted NCSC mix and MSC mix ). We first observed that transplanted cells (both NCSC mix and MSC mix ) staid tightly confined to the engraftment site, without any evident signs of migration through the brain tissue: no grafted cells were recovered into the lesioned SNpc or anywhere else inside the brain. As observed on Fig. 3.B, around 10% of NCSC mix survived up to 7 days post-graft and 3% up to 14 days. After that delay, less than 1% of NCSC mix were detected. Similar results were observed for MSC mix as the mean survival rate of grafted cells was evaluated at 10% after 3 days. The survival rate at 7 days post-graft was decreased to 3%, and no grafted MSC were detected at 14 days post-graft. Control mice (injected with saline instead of MPTP) were also grafted with the same number of NCSC mix or MSC mix and we observed that the cells also disappeared within a 28 days timeframe (Fig. S1). As the stability of CTG fluorescence with time could be questioned, we confirmed by PCR that the cells were totally gone from the brain starting from 14 days after transplantation. In that purpose, we microdissected transplanted striatum slices and we showed that no PGK-Neo signal was observed starting from 14 days post transplantation (in saturating conditions) (Fig. 3.B).

Phenotypic Characterization of Grafted MSC mix /NCSC mix
At each time point post-transplantation, grafted NCSC mix and MSC mix were tested for nestin, glial fibrillary acidic protein (GFAP), bIII-tubulin, and tyrosine hydroxylase (TH) immunoreactivity. Similar results than the one observed in vitro were recovered as transplanted NCSC mix expressed nestin (Fig. 4.E) while MSC mix did not (Fig. 4.I) [22], and both types of cells were GFAP-negative (Fig. 4.F,J). Regarding bIII-tubulin expression, specific co-localization was more difficult to appreciate since the environing brain tissue was entirely immunoreactive. However, only few positive cells were observed for NCSC mix (Fig 4.G), and no evidence was noticed for MSC mix (Fig. 4.K). Finally, no grafted cell (neither NCSC mix nor MSC mix ) differentiated into functional dopaminergic cells, as attested by their negativity for TH marker (Fig. 4.H,L and Fig. S2). According to those results, it appeared that the in vivo environment (MPTP-lesioned striatum) did not induce any modification in the phenotype of transplanted NCSC mix and MSC mix .

Effects of Cell Graft on MPTP-induced Lesions
We evaluated the integrity of nigro-striatal pathway thanks to the immunolabelling of tyrosine hydroxylase (TH). As already mentioned, the number of TH-positive neurons in the SNpc of underwent recombination, conversely to MSC mix (B). NCSC mix were b-galactosidase positive (blue, C), whereas MSC mix were not (blue, K) (Hematoxylin-stained nuclei). NCSC mix expressed neural crest-associated proteins Sox10 (green, D), Nestin (green, E) and p75NTR (green, F). MSC mix were Sox10-negative (green, L), weakly p75NTR-positive (green, N), and only a small proportion (,15%) of cells expressed nestin (green, M). MSC mix also expressed Sca-1 (green, O) and CD24 (green, P) while NCSC mix did not (green, G-H), and both types of cells were positive for Fzd-4 (green, I-Q). In NCSC mix , some b-tubulin-expressing cells were detected (in MesenCult medium) (green, J), but no cell in the MSC mix was b-tubulin-positive in those conditions (green, R) (DAPI-stained nuclei). (Scale bars = 30 mm). doi:10.1371/journal.pone.0064723.g001  Adult C57Bl/6J male mice were injected with MPTP following the ''classical'' acute regimen. Five days after MPTP treatment MSC mix /NCSC mix were injected into the right striatum of mice (MSC mix were first stained with Cell Tracker Green in order to be detected in vivo). Survival rate evaluation and phenotypic characterization were performed at different delays post-graft. B. The number of surviving NCSC mix in the right striatum (blue X-gal staining and purple Hematoxylin-stained nuclei) can reach 15% in the first week after transplantation, then the cells begin to disappear and after 4 weeks, we only observe a mean survival rate of 1%. Results are expressed in %, according to the 5610 4 injected cells (Mean 6 SEM). MSC mix (green CTG staining, blue DAPI-stained nuclei) seem to MPTP-treated animals was decreased for more than 50%, compared to control animals, and the dopaminergic fibers in the striatum nearly completely disappeared (Fig. 5.A). After 28 and even 70 days following the cell transplantation, no improvement in striatal TH staining was observed in MPTP-injected mice in both conditions (NCSC mix -grafted group, Fig. 5.B and MSC mix -grafted group, Fig. 5. C). Similarly, we did not see any significant modification in the number of host TH-positive cell bodies into the SNpc of MPTP mice that received cell grafts (Fig. 5.D) (Kruskal-Wallis ANOVA, p.0,05).

Discussion
Adult bone marrow stromal cells (BMSC) are of significant interest in cell therapy, regarding their accessible location, low immunogenicity and multipotentiality. Previous studies already described their neural differentiation abilities [27,28], then confirming their potential use in the treatment of neurological diseases. Moreover, the presence of neural crest derived cells into the adult bone marrow stroma [21,22] raised new hopes to obtain functional neurons from autologous adult stem cells [8]. Recently, a clinical trial described unilateral transplantation of autologous whole BMSC population into the subventricular zone (SVZ) of PD patients, and reported reserved clinical improvement with no adverse effects, such as tumor formation [29,30]. Whereas those results were based on clinical observations and Unified Parkinson's disease Rate Scale scores, the mechanisms underlying the reported improvements are completely unknown.
To the light of those observations, the main objective of this study was to determine if bone marrow neural crest stem cells (NCSC) were responsible for the positive impact of bone marrow stromal cells in several PD models rather than mesenchymal stem cells (MSC). In this study, we addressed the aspect of neural differentiation abilities of pure NCSC or MSC populations by directly injecting those cells into the lesioned brain. In this purpose, the model we selected was an acute lesion of dopaminergic system, induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) injection [23,31,32]. Consequently, cells were grafted five days after MPTP injection in order to pass up ongoing cell death and acute inflammatory events [33][34][35], with the aim of disappear more rapidly than NCSC mix , since no cells were observed starting from 14 days. (n$3 for each group, at each delay post-transplantation). As CTG relevancy might be questioned, the temporary survival of cells was confirmed by PCR amplification of the PGK-Neomycin cassette in grafted MSC mix . (CC = Corpus callosum; LV = Lateral ventricle; Scale bars = 500 mm). doi:10.1371/journal.pone.0064723.g003 Figure 4. In vivo characterization of brain-injected NCSC mix and MSC mix . All cells were implanted in the correct brain site, in each mouse that was included in the study. Transplanted NCSC mix were detected by X-gal staining (blue) and MSC mix were identified thanks to CTG staining (green). Grafted cells conserved their in vitro phenotype, whatever the delay post-transplantation : NCSC mix were nestin-positive (brown, A) whereas MSC mix were not (red, I). No cells did differentiate into GFAP-positive cells (NCSC mix , brown, F; MSC mix , red, J). Only few positive cells in NCSC mix were bIII-tubulin-positive (brown, G), and no specific positivity was noticed for MSC mix (red, K). Finally, grafted cells were negative for TH (NCSC mix , brown, F; MSC mix , red, J). Nestin and GFAP staining (brown or red) are detected around the transplanted cells and are linked with injection-induced inflammation (n$3 for each group, at each delay post-transplantation). Scale bars = 25 mm. doi:10.1371/journal.pone.0064723.g004 confirming if a potential enhancement was properly due to phenotypic plasticity and neural differentiation of injected cells. In those conditions, neither NCSC nor MSC survived for more than 28 days into the lesioned brain, neither underwent phenotypic modifications compared to their in vitro state before graft. Therefore, it wasn't surprising not to observe any enhancement in nigro-striatal pathway integrity, suggesting that NCSC and MSC were not able to successfully differentiate into neural cells and to integrate and connect with host neurons in acute MPTPtreated mice.
Discrepancies of our observations with previous studies [36] could be justified regarding the chronic MPTP-injection protocol that leads to completely different degeneration kinetics [37]. Indeed, acute-MPTP mouse model do not reflect a real phenomenon of progressive degeneration, we might miss several events that could prompt grafted cells to adapt their phenotype. On the other hand, grafting stem cells in chronic-MPTP mice would be trickier to characterize, as both neuroprotective and neurorestorative events could simultaneously occur.
Nonetheless, our results reinforce the current controversy on BMSC neural differentiation ability. Indeed, whereas loads of papers describe in vitro specific neural proteins expression in BMSC after various neural induction protocols [38][39][40][41], few data provide convincing evidence for a neuron-specific electrophysiological signature of the differentiated cells, namely the elicitation of action potentials [42]. Moreover, the expression of neural specific proteins fails to characterize authentic functional and mature neurons, as some neural markers are already observed in primary cultures (without any differentiation protocols) [43,44] and even after mesenchymal differentiation [45].
Concerning preclinical cell therapy experiments on PD animals models, neural differentiation-based therapy protocols were performed using stem cells from Wharton's Jelly [46], dental pulp [47] and bone marrow [9,48] that underwent various culture conditions before being transplanted in 6-hydroxydopamine (6-OHDA)-treated rats. Behavioral and pathological enhancements were observed in most of the studies, but the underlying mechanisms were not sufficiently detailed, and no evidence for an appropriate integration into the lesioned central nervous system (CNS) was observed. Conversely, significant improvements were observed in PD animal models that were transplanted with BMSC without any pre-differentiation step. In those conditions, no sign of neural differentiation was properly observed. Still, beneficial effects and rescue of dopaminergic neurons were noticed and mainly associated with neuroprotection [49,50], trophic support (i.e. glial cell line-derived neurotrophic factor (GDNF) or epidermal growth factor (EGF) secretion) [50,51] or antiinflammation (attenuation of blood-brain barrier damages, microglia inactivation) [52]. Moreover, BMSC graft induced proliferation and migration of endogenous SVZ neuroblasts in two PD animal models [50,53].
As regards the recent data about PD models and BMSC-based cell therapy, it appears that neural differentiation might not be responsible for physiopathological and clinical recoveries that are observed after BMSC transplantation in PD experimental models. Indeed, no evidence for in vivo functional neuronal replacement and CNS integration has been provided so far. Our results confirmed that bone marrow NCSC (in a pure population) are not any more competent than pure MSC nor whole BMSC to differentiate into neurons and integrate the damaged dopaminergic system. Altogether, it looks like adult BMSC are not a prime option for cell replacement therapies in the context of Parkinson's disease. However, neuroprotective, neurotrophic and anti-inflam-matory features characterizing BMSC are of greater interest as regards CNS lesions management, and still need to be fully characterized [54]. Figure S1 Survival rate of grafted cells at 3, 7, 14, 28 and 70 days after transplantation of MSC mix /NCSC mix in MPTP and control mice. A. In MPTP mice, the number of surviving NCSC mix in the right striatum (blue X-gal staining and purple Hematoxylin-stained nuclei) can reach 15% in the first week after transplantation, then the cells begin to disappear and after 4 weeks, we only observe a mean survival rate of 1%. In control mice, even if the number of surviving cells is higher at 3 and 7 days post-graft, the survival rate also decreases to 1% after 28 days. B. MSC mix (green CTG staining, blue DAPI-stained nuclei) seem to disappear more rapidly than NCSC mix , since no cells were observed starting from 14 days, in both MPTP and control mice. C. Number of grafted cells that were recovered in mice brains at different delays post transplantation (Mean 6 SEM) (CC = Corpus callosum; LV = Lateral ventricle; Scale bars = 500 mm). (TIF) Figure S2 Tyrosine hydroxylase staining of brain-injected NCSC mix , at different delays post transplantation. Transplanted NCSC mix were detected by X-gal staining (blue). Grafted cells were negative for TH (brown) at 3, 7, 14 and 28 days after the cell injection (n$3 for each group, at each delay posttransplantation). (Scale bars = 100 mm). (TIF)